Posted by Michael Wonder on 07 Sep 2022
CDER and CBER accept first submission to ISTAND pilot program
7 September 2022 - The FDA’s Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research have accepted the agency’s first submission into the Innovative Science and Technology Approaches for New Drugs (ISTAND) Pilot Program.
FDA launched ISTAND in 2020 to support development of drug development tools that are considered novel to be used in regulatory applications for new medical products.
